Best Business Valuation Software for Startups
From First Raise to 409A — Every Stage Covered.
Startups need valuations at every stage: pre-revenue fundraising, option pool grants, Series A due diligence, secondary transactions, and exit. Each stage demands a different methodology. This guide covers the platforms, the methods, and what actually matters at each stage.
Also see: vs. Equidam · vs. Claude AI · vs. Kroll · vs. PitchBook / CapIQ
Why Startup Valuation Is Different From Every Other Valuation
Valuing an established business with three years of EBITDA is methodologically straightforward. Valuing a startup — with no revenue, no comparable transactions, an unproven market, and a cap table full of preferences and warrants — requires a completely different set of tools.
Most valuation platforms were built for established businesses. They apply DCF to historical cash flows, benchmark against public comparables, and produce a market-multiple-based range. For a pre-revenue startup, this workflow either produces a meaningless output or fails to run at all.
The right valuation platform for a startup needs to handle the full lifecycle: Berkus and Scorecard methods for pre-revenue seed, First Chicago and Venture Capital Method for Series A and B, DCF with high-growth assumptions for later stages, OPM (Option Pricing Model) for complex cap structures, and a standalone 409A module for every option grant along the way.
Valuation Methods by Startup Stage
| Stage | Context | Methods That Apply | In Equitest |
|---|---|---|---|
| Pre-Revenue / Seed | Idea, MVP, no revenue | Berkus Method, Scorecard Method, Risk Factor Summation | |
| Early Revenue / Series A | Product-market fit, initial ARR | First Chicago Method, Venture Capital Method, Revenue Multiples | |
| Growth Stage / Series B+ | Scaling ARR, path to profitability | DCF (high-growth), Revenue/EBITDA Multiples, OPM, Monte Carlo | |
| Option Grant / IRC §409A | Issuing stock options to employees | 409A — backsolve, OPM, PWERM (multi-scenario) | Native module |
| Secondary / Late Stage | Secondary liquidity, pre-IPO | DCF, OPM, Public Comparable Companies, DLOM | |
| M&A / Exit | Acquisition, merger, SPAC | Full DCF, Transaction Comparables, Football Field |
How Equitest Compares to the Platforms Startups Currently Use
| What Startups Need | Equidam | Kroll (409A) | Equitest |
|---|---|---|---|
| Berkus / Scorecard (pre-revenue) | |||
| First Chicago / VC Method | |||
| IRC §409A native module | (managed engagement) | Self-serve | |
| OPM / Real Options | (managed) | ||
| DCF for growth-stage companies | Basic | (managed) | + Monte Carlo + Goal-Seek |
| Public comparable companies (SaaS, fintech, biotech) | (managed) | 50,000+ live | |
| DLOM for minority / illiquid positions | (managed) | 4 models | |
| 40-chapter institutional report | Investor summary only | Expert-signed | Auto-generated, self-serve |
| Self-serve — no advisory engagement | |||
| All stages in one platform | Seed/Series A only | 409A specialist | Seed through exit |
Why Equitest Is the Right Platform for Startup Valuation
Seed Through Exit in One Platform
Equidam covers pre-revenue and early-stage startups well — but stops at Series A. Kroll does 409A engagements for later-stage companies but requires a managed services contract. PitchBook and CapIQ give you market intelligence but don't run valuations. Every other platform on the market covers one or two stages of the startup lifecycle.
Equitest covers them all: Berkus and Scorecard for pre-revenue seed, First Chicago and VC Method for Series A, DCF with high-growth assumptions and Monte Carlo for growth stage, OPM for complex cap structures, DLOM for illiquid minority positions, a native 409A module for every option grant, and the full M&A suite for exit. One platform. Every stage.
Self-Serve IRS Compliance
IRC §409A requires a qualified independent appraisal before every significant option grant. Most startups either pay a specialist firm (Carta, Kroll, Big 4) for a managed 409A engagement — expensive and slow — or rely on a platform-generated report that may not meet IRS defensibility standards.
Equitest's native 409A module produces a standalone IRS-compliant equity compensation valuation report, self-serve, incorporating the required methodologies (backsolve, OPM, PWERM where applicable) and the documentation an IRS auditor expects to see. For a startup issuing options quarterly, this is a high-value capability that eliminates a recurring advisory expense.
Quantify the Range, Not Just the Point
A startup's value is inherently uncertain. The standard approach — build a DCF with a single set of growth assumptions and report a point estimate — understates that uncertainty and makes the valuation easy to attack. Monte Carlo simulation runs 10,000+ scenarios across the distribution of your key assumptions (growth rate, margin, discount rate) and reports a probability-weighted range with confidence intervals.
For a Series B company preparing for investor due diligence, or a growth-stage company preparing a secondary transaction, the Monte Carlo range is a more honest and more defensible representation of value than any single DCF output.
From Seed Deck to Due Diligence Package
Equitest's 40-chapter institutional report includes an executive summary appropriate for an investor presentation, full methodology disclosure suitable for due diligence, market comparables for benchmarking, and a Football Field Chart showing value range across all methods. At seed stage, you can use the executive summary. At Series B, you deliver the complete 40-chapter report. At exit, you submit it as part of the M&A data room.
The same platform, the same report architecture, calibrated to the depth the moment requires.
Illiquidity Properly Quantified
Private startup equity is illiquid. When a startup needs to value a minority position for a secondary transaction, an employee exercise, or a financial reporting requirement (ASC 820), the Discount for Lack of Marketability is a required and heavily scrutinised input.
Equitest applies DLOM using four independent quantitative models — Chaffe, Longstaff, Finnerty, and Ghaidarov — each producing a defensible, reproducible result from your specific inputs. Not a single assumed discount percentage, but a methodology-backed conclusion across four models.
Equitest Is the Right Platform If
- You are a startup CFO who needs 409A compliance without paying for a managed advisory engagement every quarter
- You are raising a Series A or B and need an institutional-grade valuation report for investor due diligence
- You need pre-revenue methods (Berkus, First Chicago, VC Method) alongside later-stage DCF and OPM
- You need Monte Carlo to present a probability-weighted range rather than a single point estimate
- You are preparing a secondary transaction and need a defensible minority interest and DLOM analysis
- You want one platform that covers seed through exit without switching tools at each stage
Consider Alternatives If
- chevron_rightYou are doing a single seed-stage fundraise and only need a simple investor-facing summary (Equidam is simpler)
- chevron_rightYour 409A requires a Big 4 or specialist advisory firm signature for regulatory or audit reasons (Kroll, Big 4)
- chevron_rightYou need PitchBook's private company database for investor intelligence and deal sourcing (separate use case)
The Bottom Line
No other platform on the market covers the full startup valuation lifecycle — from pre-revenue Berkus through exit DCF — in a single self-serve system with a native 409A module, quantitative DLOM, Monte Carlo simulation, and a 40-chapter institutional report. For startup CFOs, founders, and their advisors who need to produce defensible valuations at every stage without switching platforms or engaging advisory firms for routine work, Equitest is the platform built for that requirement.
